Bottom Line: The VA's Non-Formulary (NF) designation can be overcome through broad, compelling clinical justification demonstrating...

The Defense Health Agency’s Benefits Advisory Panel (BAP) has long served as a gatekeeper in the military health system’s formulary...

Bottom Line: By strategically collaborating with commercial Integrated Delivery Networks on pharmaceutical management, the VA is...

The VA and DoD are not “loss leader” channels. They are high-value, margin-stable, influence-rich markets where a single, well-executed...

Pharmaceutical manufacturers frequently misinterpret market opportunity within the distinct VA patient population by directly applying...

We know both VA and DoD partner with Kaiser - but how do these health systems actually compare? If you’re investing in Kaiser Permanente,...

Bottom Line: Understanding the mechanisms in which a community care provider can request extended or new medical treatments is core...

Bottomline: The VA Community Care program, while crucial for expanding veteran healthcare access, can result in reimbursement...

Bottom Line: The Department of Defense (DoD) is frequently the first federal payer to formally assess newly FDA-approved pharmaceutical...

This side-by-side chart highlights the key distinctions between the VA healthcare system and Medicare, including eligibility, coverage...

Our team recently published Part II in a 3-part series aimed at helping drug manufactures gain an updated view of VA and DOD drug...

Bottom Line: The VA's updated presumptive conditions list expanding coverage for Gulf War and Post-9/11 veterans necessitates...